The group of Kenneth A. Jacobson recently described the generation and evaluation of MRS4719 and MRS4596, two potent new P2X4 antagonists (IC50 0.503 and 1.38 μM for human P2X4, respectively) with neuroprotective effects in murine ischemic stroke (tMCAO): MRS4719 dose dependently reduced infarct size and brain atrophy 3 and 35 days post-stroke [27]. The gene discussed is P2RX4; the disease is Brain atrophy.